Duloxetine: here's the fair price
This is what US pharmacies pay, on average, for duloxetine. Use it to spot a fair cash price, and feel good about asking for one.
Duloxetine Hcl Dr 30 Mg Cap
A fair cash price is usually this cost plus a dispensing fee. If your quote is many times higher, ask about a generic, another pharmacy, or a cash discount.
Ask for generic Duloxetine Hcl Dr 30 Mg Cap. Pharmacies pay about $2.98 for 30. Ask your pharmacy for its cash price and compare it with your copay. A fair cash price is close to this cost plus a dispensing fee.
Source: CMS NADAC as of 2026-11-04. Ask your prescriber or pharmacist whether a generic is right for you.
Source: CMS NADAC weekly file as of 2026-11-04. Median across NDCs with the same description. Public domain.
Your ZIP and location stay in your browser. We never store them.
Every strength and form
| Product | Pharmacy cost | 30 count | Effective |
|---|---|---|---|
| DULOXETINE HCL DR 30 MG CAPGeneric | $0.10 per tablet or capsule | $2.98 | 10/28/2026 |
| DULOXETINE HCL DR 20 MG CAPGeneric | $0.12 per tablet or capsule | $3.54 | 10/28/2026 |
| DULOXETINE HCL DR 60 MG CAPGeneric | $0.14 per tablet or capsule | $4.10 | 10/28/2026 |
| DULOXETINE HCL DR 40 MG CAPGeneric | $1.21 per tablet or capsule | $36.44 | 10/21/2026 |
| DULOXETINE HCL DR 90 MG CAPGeneric | $5.65 per tablet or capsule | $169.55 | 10/21/2026 |
| DULOXETINE HCL DR 120 MG CAPGeneric | $5.66 per tablet or capsule | $169.80 | 10/21/2026 |
Source: CMS NADAC, as of 2026-11-04. National average acquisition cost, not a retail quote.
Label basics
What it is used for (FDA label)
1 INDICATIONS AND USAGE Duloxetine delayed-release capsules are indicated for the treatment of: Major depressive disorder in adults Generalized anxiety disorder in adults and pediatric patients 7 years of age and older Diabetic peripheral neuropathic pain in adults Fibromyalgia in adults Chronic musculoskeletal pain in adults Duloxetine delayed-release capsules are a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of the following conditions: Major depressive disorder (MDD) in adults (1) Generalized anxiety disorder (GAD) in adults and pediatric patients 7 years of age and older (1) Diabetic peripheral neuropathic pain (DPNP) in adults (1) Fibromyalgia...
Common side effects (FDA label)
6 ADVERSE REACTIONS The following serious adverse reactions are described below and elsewhere in the labeling: Suicidal Thoughts and Behaviors in Children, Adolescents, and Young Adults [see Boxed Warning and Warnings and Precautions (5.1)] Hepatotoxicity [see Warnings and Precautions (5.2)] Orthostatic Hypotension, Falls and Syncope [see Warnings and Precautions (5.3)] Serotonin Syndrome [see Warnings and Precautions (5.4)] Increased Risk of Bleeding [see Warnings and Precautions (5.5)] Severe Skin Reactions [see Warnings and Precautions (5.6)] Discontinuation Syndrome [see Warnings and...
Drug interactions (from the label)
7 DRUG INTERACTIONS Both CYP1A2 and CYP2D6 are responsible for duloxetine metabolism. Potent inhibitors of CYP1A2 should be avoided (7.1). Potent inhibitors of CYP2D6 may increase duloxetine concentrations (7.2). Duloxetine is a moderate inhibitor of CYP2D6 (7.9). 7.1 Inhibitors of CYP1A2 When duloxetine delayed-release capsules 60 mg was co-administered with fluvoxamine 100 mg, a potent CYP1A2 inhibitor, to male subjects (n=14) duloxetine AUC was increased approximately 6-fold, the C max was increased about 2.5-fold, and duloxetine t 1/2 was increased approximately 3-fold. Other drugs that inhibit CYP1A2 metabolism include cimetidine and quinolone antimicrobials such as ciprofloxacin and...
Warnings (from the label)
5 WARNINGS AND PRECAUTIONS Hepatotoxicity : Hepatic failure, sometimes fatal, has been reported. Discontinue duloxetine delayed-release capsule in patients who develop jaundice or other evidence of clinically significant liver dysfunction and should not be resumed unless another cause can be established. Avoid use in patients with substantial alcohol use or evidence of chronic liver disease (5.2) Orthostatic Hypotension, Falls and Syncope : Consider dosage reduction or discontinuation if these events occur (5.3) Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also when taken alone. If it occurs, discontinue...
Source: FDA drug label via openFDA, label effective 2026-04-22. Full label on DailyMed. Excerpts are verbatim and truncated. Read the full label and ask your pharmacist.